

Francis X McCormack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1037986/publications.pdf>

Version: 2024-02-01

199
papers

13,771
citations

36691

53
h-index

25983

112
g-index

205
all docs

205
docs citations

205
times ranked

9620
citing authors

#	ARTICLE	IF	CITATIONS
1	A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant. <i>Respiratory Medicine</i> , 2022, 195, 106779.	1.3	1
2	Serum Vascular Endothelial Growth Factor C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2021, 18, 174-177.	1.5	3
3	Neoplasms That Present as Multicystic Lung Disease. <i>Respiratory Medicine</i> , 2021, , 215-238.	0.1	0
4	Definition and Classification of Diffuse Cystic Lung Diseases. <i>Respiratory Medicine</i> , 2021, , 1-19.	0.1	0
5	Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2021, 18, 815-819.	1.5	10
6	Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1313-1327.	5.2	67
7	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	1.0	230
8	Oral Positive Expiratory Pressure Device for Excessive Dynamic Airway Collapse Caused by Emphysema. <i>Chest</i> , 2021, 160, e333-e337.	0.4	3
9	Machine learning can predict disease manifestations and outcomes in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2021, 57, 2003036.	3.1	6
10	Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis. <i>Respiratory Medicine</i> , 2021, 190, 106683.	1.3	5
11	Viral Evasion of Innate Immune Defense: The Case of Resistance of Pandemic H1N1 Influenza A Virus to Human Mannose-Binding Proteins. <i>Frontiers in Microbiology</i> , 2021, 12, 774711.	1.5	2
12	Successful Response to Treatment with Sirolimus in Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e119-e120.	2.5	14
13	Pulmonary alveolar microlithiasis. <i>European Respiratory Review</i> , 2020, 29, 200024.	3.0	19
14	Eight novel variants in the <i>SLC34A2</i> gene in pulmonary alveolar microlithiasis. <i>European Respiratory Journal</i> , 2020, 55, 1900806.	3.1	14
15	Single-Cell Transcriptomic Analysis Identifies a Unique Pulmonary Lymphangioleiomyomatosis Cell. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1373-1387.	2.5	63
16	A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. <i>Respiratory Medicine</i> , 2020, 163, 105898.	1.3	8
17	Pulmonary Alveolar Microlithiasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 280-287.	0.8	6
18	MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. <i>JCI Insight</i> , 2020, 5, .	2.3	24

#	ARTICLE	IF	CITATIONS
19	The emergence of targetable <sc>MEK</sc> anisms in sporadic lymphatic disorders. <i>EMBO Molecular Medicine</i> , 2020, 12, e12822.	3.3	6
20	The NHLBI LAM Registry. <i>Chest</i> , 2019, 155, 288-296.	0.4	67
21	Structural and Functional Determinants of Rodent and Human Surfactant Protein A: A Synthesis of Binding and Computational Data. <i>Frontiers in Immunology</i> , 2019, 10, 2613.	2.2	13
22	Cyst Ventilation Heterogeneity and Alveolar Airspace Dilation as Early Disease Markers in Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1008-1016.	1.5	21
23	Recurrent Sinusitis, Lower Limb Edema, and Nail Changes. <i>Annals of the American Thoracic Society</i> , 2019, 16, 752-755.	1.5	1
24	Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. <i>PLoS ONE</i> , 2019, 14, e0212776.	1.1	14
25	Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1151-1152.	2.5	6
26	Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2019, 53, 1802066.	3.1	41
27	Lymphangioleiomyomatosis Mortality in Patients with Tuberous Sclerosis Complex. <i>Annals of the American Thoracic Society</i> , 2019, 16, 509-512.	1.5	9
28	Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1507-1508.	2.5	3
29	NKG2D Regulation of Lung Pathology and Dendritic Cell Function Following Respiratory Syncytial Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, 1822-1832.	1.9	5
30	Smoking-Related Diffuse Cystic Lung Disease. <i>Chest</i> , 2018, 154, e31-e35.	0.4	15
31	The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2018, 52, 1800951.	3.1	13
32	Lymphangioleiomyomatosis: A Monogenic Model of Malignancy. <i>Annual Review of Medicine</i> , 2017, 68, 69-83.	5.0	55
33	Treatment of Lymphangioleiomyomatosis (LAM). <i>Milestones in Drug Therapy</i> , 2017, , 239-263.	0.1	0
34	Spontaneous Pneumothoraces in Patients with Birt-Hogg-Dubé Syndrome. <i>Annals of the American Thoracic Society</i> , 2017, 14, 706-713.	1.5	67
35	Dendritic Cell Trafficking and Function in Rare Lung Diseases. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 393-402.	1.4	20
36	A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2017, 14, 919-928.	1.5	24

#	ARTICLE	IF	CITATIONS
37	Reply: The ATS/JRS Guidelines on Lymphangiomyomatosis: Filling in the Gaps. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 660-661.	2.5	0
38	Sirinolimus for the treatment of lymphangiomyomatosis. Expert Opinion on Orphan Drugs, 2017, 5, 907-921.	0.5	8
39	Thermal injury of the skin induces G-CSF-dependent attenuation of EPO-mediated STAT signaling and erythroid differentiation arrest in mice. Experimental Hematology, 2017, 56, 16-30.	0.2	9
40	Differential Ligand Binding Specificities of the Pulmonary Collectins Are Determined by the Conformational Freedom of a Surface Loop. Biochemistry, 2017, 56, 4095-4105.	1.2	8
41	An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. Annals of the American Thoracic Society, 2017, 14, 1239-1247.	1.5	4
42	Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6613-E6622.	3.3	30
43	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in Experimental Medicine and Biology, 2017, 1031, 419-442.	0.8	10
44	Lymphangiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1337-1348.	2.5	159
45	Apparent Sporadic Lymphangiomyomatosis (LAM) in a Man Due to Extreme Mosaicism for a <i>TSC2</i> Mutation. Annals of the American Thoracic Society, 2017, 14, 1227-1229.	1.5	6
46	Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective. Annals of the American Thoracic Society, 2017, 14, 17-25.	1.5	44
47	Unsupervised gene expression analyses identify IPF-severity correlated signatures, associated genes and biomarkers. BMC Pulmonary Medicine, 2017, 17, 133.	0.8	27
48	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight, 2017, 2, e89473.	2.3	63
49	Hsp90 regulation of fibroblast activation in pulmonary fibrosis. JCI Insight, 2017, 2, e91454.	2.3	73
50	Summary for Clinicians: Lymphangiomyomatosis Diagnosis and Management Clinical Practice Guideline. Annals of the American Thoracic Society, 2017, 14, 1073-1075.	1.5	6
51	Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model of Distal Nephron Salt Wasting. PLoS ONE, 2016, 11, e0159804.	1.1	3
52	Keratinocyte growth factor supports pulmonary innate immune defense through maintenance of alveolar antimicrobial protein levels and macrophage function. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L868-L879.	1.3	19
53	Pulmonary Alveolar Microlithiasis. Clinics in Chest Medicine, 2016, 37, 441-448.	0.8	37
54	Nonmalignant Adult Thoracic Lymphatic Disorders. Clinics in Chest Medicine, 2016, 37, 409-420.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1912-1922.	1.5	42
56	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 748-761.	2.5	236
57	Diagnosis and Treatment of Lymphatic Plastic Bronchitis in Adults Using Advanced Lymphatic Imaging and Percutaneous Embolization. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1689-1696.	1.5	69
58	Rare Lung Diseases: Occasionally the "Horse" Has Stripes. <i>Clinics in Chest Medicine</i> , 2016, 37, xv-xvi.	0.8	0
59	Elucidation of Lipid Binding Sites on Lung Surfactant Protein A Using X-ray Crystallography, Mutagenesis, and Molecular Dynamics Simulations. <i>Biochemistry</i> , 2016, 55, 3692-3701.	1.2	25
60	Diffuse Cystic Lung Disease as the Presenting Manifestation of Sjögren Syndrome. <i>Annals of the American Thoracic Society</i> , 2016, 13, 371-375.	1.5	22
61	A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2016, 13, 342-349.	1.5	25
62	Lymphangioleiomyomatosis. , 2016, , 1243-1259.e12.		1
63	NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. <i>JCI Insight</i> , 2016, 1, e87270.	2.3	21
64	Real-Time Genomic Profiling Identifies Novel Mutations and Improved Therapy for Histiocytoses. <i>Blood</i> , 2016, 128, 2723-2723.	0.6	0
65	Unraveling the Dual Role of Surfactant Protein a at Atomistic Detail. <i>Biophysical Journal</i> , 2015, 108, 255a-256a.	0.2	0
66	The importance of biobank and nationwide registry for lymphangioleiomyomatosis in a small sized country. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 393-401.	0.5	2
67	Oral Administration of Surfactant Protein A Reduces Pathology in an Experimental Model of Necrotizing Enterocolitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015, 60, 613-620.	0.9	20
68	A 25-Year-Old Man with Fatigue, Dyspnea, and Pulmonary Cysts. <i>Annals of the American Thoracic Society</i> , 2015, 12, 120-123.	1.5	1
69	Keratinocyte Growth Factor Administration Attenuates Murine Pulmonary Mycobacterium tuberculosis Infection through Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF)-dependent Macrophage Activation and Phagolysosome Fusion. <i>Journal of Biological Chemistry</i> , 2015, 290, 7151-7159.	1.6	17
70	Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. <i>European Respiratory Journal</i> , 2015, 46, 783-794.	3.1	83
71	Diffuse Cystic Lung Disease. Part I. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1354-1366.	2.5	154
72	Diffuse Cystic Lung Disease. Part II. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 17-29.	2.5	117

#	ARTICLE	IF	CITATIONS
73	Accuracy of chest high-resolution computed tomography in diagnosing diffuse cystic lung diseases. <i>European Respiratory Journal</i> , 2015, 46, 1196-1199.	3.1	35
74	Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment. <i>Science Translational Medicine</i> , 2015, 7, 313ra181.	5.8	44
75	SP-R210 (Myo18A) Isoforms as Intrinsic Modulators of Macrophage Priming and Activation. <i>PLoS ONE</i> , 2015, 10, e0126576.	1.1	20
76	Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1247-8.	1.5	1
77	Kaposiform Lymphangiomas, a Newly Characterized Vascular Anomaly Presenting with Hemoptysis in an Adult Woman. <i>Annals of the American Thoracic Society</i> , 2014, 11, 92-95.	1.5	36
78	Successful Management of a Chronic, Refractory Bronchopleural Fistula with Endobronchial Valves followed by Talc Pleurodesis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 490-491.	2.5	5
79	Chronic Sirolimus Therapy for Lymphangiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1332-1333.	2.5	7
80	G-CSF Drives a Posttraumatic Immune Program That Protects the Host from Infection. <i>Journal of Immunology</i> , 2014, 192, 2405-2417.	0.4	29
81	Mutations flanking the carbohydrate binding site of surfactant protein D confer antiviral activity for pandemic influenza A viruses. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L1036-L1044.	1.3	19
82	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
83	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693
84	Serum VEGF-D concentration as a biomarker of lymphangiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangiomyomatosis Efficacy of Sirolimus (MILES) trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 445-452.	5.2	159
85	Clinical Predictors of Mortality and Cause of Death in Lymphangiomyomatosis: A Population-based Registry. <i>Lung</i> , 2013, 191, 35-42.	1.4	69
86	Pulmonary manifestations of Birt-Hogg-Dubé syndrome. <i>Familial Cancer</i> , 2013, 12, 387-396.	0.9	100
87	Birt-Hogg-Dubé syndrome. <i>Familial Cancer</i> , 2013, 12, 355-356.	0.9	6
88	Pulmonary Vascular Shunts in Exercise-Intolerant Patients with Lymphangiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1167-1170.	2.5	8
89	An Atoll Variant That Mocks. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 110-110.	2.5	0
90	Reply: Characterization of Lymphangiomyomatosis as a Neoplastic Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 398-399.	2.5	0

#	ARTICLE	IF	CITATIONS
91	Pulmonary Alveolar Microlithiasis. American Journal of Respiratory and Critical Care Medicine, 2013, 188, e11-e12.	2.5	5
92	St. George's Respiratory Questionnaire Has Longitudinal Construct Validity in Lymphangioleiomyomatosis. Chest, 2013, 143, 1671-1678.	0.4	16
93	Lymphangioleiomyomatosis Screening in Women With Tuberous Sclerosis. Chest, 2013, 144, 578-585.	0.4	129
94	Lymphangioleiomyomatosis â€” a wolf in sheepâ€™s clothing. Journal of Clinical Investigation, 2012, 122, 3807-3816.	3.9	258
95	Lymphangioleiomyomatosis: New Concepts in Pathogenesis, Diagnosis, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 486-497.	0.8	65
96	The Alveolar Epithelium Determines Susceptibility to Lung Fibrosis in Hermansky-Pudlak Syndrome. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1014-1024.	2.5	94
97	Lymphangioleiomyomatosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1210-1212.	2.5	168
98	Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Frontiers of Medicine, 2012, 6, 395-405.	1.5	35
99	Mechanisms of Interaction Between Lung Collectins and Influenza a Virus Hemagglutinin. Biophysical Journal, 2011, 100, 214a-215a.	0.2	0
100	Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis. New England Journal of Medicine, 2011, 364, 1595-1606.	13.9	922
101	Diffuse Cystic Lung Disease at High-Resolution CT. American Journal of Roentgenology, 2011, 196, 1305-1311.	1.0	125
102	Unraveling the Specific Interactions of Collectin with Lipopolysaccharides. Biophysical Journal, 2011, 100, 511a.	0.2	0
103	Diagnostic Yield Of Transbronchial Biopsy In Patients With Pulmonary Lymphangioleiomyomatosis. , 2011, , .		0
104	KGF Enhances Pandemic Influenza (H1N1) Induced Mortality In Mice. , 2011, , .		0
105	Baseline Serum VEGF-D Levels Are Associated With Disease Severity And Treatment Response In Lymphangioleiomyomatosis. , 2011, , .		1
106	Sensitivity Of Limited Section HRCT To Diagnose Lymphangioleiomyomatosis (LAM) In Women With Tuberous Sclerosis Complex. , 2011, , .		0
107	Keratinocyte Growth Factor Attenuates Murine Pulmonary Mycobacterium Tuberculosis Infection Through GM-CSF Dependent Mechanisms. , 2011, , .		0
108	Susceptibility To Alveolar Type II Cell Apoptosis And Pulmonary Fibrosis In Naturally Occurring Hermansky Pudlak Syndrome Mice Is Not Associated With Endoplasmic Reticulum Stress. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
109	Vitamin D Deficiency and Reduced Lung Function in Connective Tissue-Associated Interstitial Lung Diseases. <i>Chest</i> , 2011, 139, 353-360.	0.4	34
110	Multicenter International Lymphangiomyomatosis Efficacy And Safety Of Sirolimus (MILES) Trial. , 2011, , .		0
111	Keratinocyte Growth Factor Augments Pulmonary Innate Immunity through Epithelium-driven, GM-CSF-dependent Paracrine Activation of Alveolar Macrophages. <i>Journal of Biological Chemistry</i> , 2011, 286, 14932-14940.	1.6	24
112	Mutagenesis of Surfactant Protein D Informed by Evolution and X-ray Crystallography Enhances Defenses against Influenza A Virus in Vivo. <i>Journal of Biological Chemistry</i> , 2011, 286, 40681-40692.	1.6	36
113	Crystallographic Complexes of Surfactant Protein A and Carbohydrates Reveal Ligand-induced Conformational Change. <i>Journal of Biological Chemistry</i> , 2011, 286, 757-765.	1.6	20
114	O caminho À frente da linfangioleiomiomatose: um ensaio para cada paciente, cada paciente em um ensaio. <i>Jornal Brasileiro De Pneumologia</i> , 2011, 37, 422-423.	0.4	3
115	Serum Vascular Endothelial Growth Factor-D Prospectively Distinguishes Lymphangiomyomatosis From Other Diseases. <i>Chest</i> , 2010, 138, 674-681.	0.4	188
116	Endobronchial Carcinoid Tumor in an HIV-infected Patient. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2010, 17, 174-176.	0.8	3
117	Clinical Trials for Rare Lung Diseases: Lessons from Lymphangiomyomatosis. <i>Lymphatic Research and Biology</i> , 2010, 8, 71-79.	0.5	12
118	Review: Structural determinants of pattern recognition by lung collectins. <i>Innate Immunity</i> , 2010, 16, 143-150.	1.1	63
119	Tuberous Sclerosis Complex: Neurological, Renal and Pulmonary Manifestations. <i>Neuropediatrics</i> , 2010, 41, 199-208.	0.3	118
120	Screening for Lymphangiomyomatosis by High-Resolution Computed Tomography in Young, Nonsmoking Women Presenting with Spontaneous Pneumothorax Is Cost-Effective. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1376-1382.	2.5	40
121	Predictors for clinical trial participation in the rare lung disease lymphangiomyomatosis. <i>Respiratory Medicine</i> , 2010, 104, 578-583.	1.3	20
122	Lymphangiomyomatosis. , 2010, , 85-110.		0
123	Lymphangiomyomatosis. , 2010, , 1496-1515.		0
124	Surfactant Protein A Modulates Cell Surface Expression of CR3 on Alveolar Macrophages and Enhances CR3-mediated Phagocytosis. <i>Journal of Biological Chemistry</i> , 2009, 284, 7495-7504.	1.6	47
125	Automated Algorithm for Quantifying the Extent of Cystic Change on Volumetric Chest CT: Initial Results in Lymphangiomyomatosis. <i>American Journal of Roentgenology</i> , 2009, 192, 1037-1044.	1.0	31
126	IRRAS Studies of the Host Defense Effect of Pulmonary Surfactants SP-A and SP-D. <i>Biophysical Journal</i> , 2009, 96, 595a.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Utility of [18 F]2-Fluoro-2-Deoxyglucose-PET in Sporadic and Tuberous Sclerosis-Associated Lymphangioleiomyomatosis. <i>Chest</i> , 2009, 136, 926-933.	0.4	33
128	Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2009, 135, 1557-1563.	0.4	189
129	Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2008, 358, 140-151.	13.9	1,138
130	Lymphangioleiomyomatosis. <i>Chest</i> , 2008, 133, 507-516.	0.4	285
131	Diagnostic Potential of Serum VEGF-D for Lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2008, 358, 199-200.	13.9	122
132	Variability in the Prevalence of Acute Bronchoresponsiveness in Different Populations of Patients With Lymphangioleiomyomatosis: Response. <i>Chest</i> , 2008, 134, 218.	0.4	2
133	Air travel in women with lymphangioleiomyomatosis. <i>Thorax</i> , 2007, 62, 176-180.	2.7	45
134	Susceptibility of Hermansky-Pudlak Mice to Bleomycin-Induced Type II Cell Apoptosis and Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 67-74.	1.4	56
135	S-LAM in a Man?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 3-5.	2.5	12
136	Molecular Pathogenesis of Lymphangioleiomyomatosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 36, 398-408.	1.4	91
137	MANAGEMENT PREFERENCES FOR PLEURAL INTERVENTION PRIOR TO LUNG TRANSPLANTATION IN LYMPHANGIOLEIOMYOMATOSIS. <i>Chest</i> , 2007, 132, 620A.	0.4	0
138	The Resident Scholar Program: A research training opportunity for Internal Medicine house staff. <i>Journal of Cancer Education</i> , 2007, 22, 47-49.	0.6	20
139	The Flagellum of <i>Pseudomonas aeruginosa</i> Is Required for Resistance to Clearance by Surfactant Protein A. <i>PLoS ONE</i> , 2007, 2, e564.	1.1	38
140	Pleural Disease in Lymphangioleiomyomatosis. <i>Clinics in Chest Medicine</i> , 2006, 27, 355-368.	0.8	48
141	Pulmonary Collectins Selectively Permeabilize Model Bacterial Membranes Containing Rough Lipopolysaccharide. <i>Biochemistry</i> , 2006, 45, 2679-2685.	1.2	30
142	Neither SP-A nor NH ₂ -terminal domains of SP-A can substitute for SP-D in regulation of alveolar homeostasis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2006, 291, L181-L190.	1.3	20
143	Management of Pneumothorax in Lymphangioleiomyomatosis. <i>Chest</i> , 2006, 129, 1274-1281.	0.4	146
144	New concepts in collectin-mediated host defense at the air-liquid interface of the lung. <i>Respirology</i> , 2006, 11, S7-S10.	1.3	13

#	ARTICLE	IF	CITATIONS
145	Microfibril-associated Protein 4 Binds to Surfactant Protein A (SP-A) and Colocalizes with SP-A in the Extracellular Matrix of the Lung. <i>Scandinavian Journal of Immunology</i> , 2006, 64, 104-116.	1.3	53
146	Patient Perspectives on Management of Pneumothorax in Lymphangiomyomatosis. <i>Chest</i> , 2006, 129, 1267-1273.	0.4	34
147	The NHLBI Lymphangiomyomatosis Registry. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 105-111.	2.5	405
148	Antimicrobial Activity of Native and Synthetic Surfactant Protein B Peptides. <i>Journal of Immunology</i> , 2006, 176, 416-425.	0.4	62
149	Correction of Pulmonary Abnormalities in Sftpd ^{-/-} Mice Requires the Collagenous Domain of Surfactant Protein D. <i>Journal of Biological Chemistry</i> , 2006, 281, 24496-24505.	1.6	50
150	Lung-Restricted Macrophage Activation in the Pearl Mouse Model of Hermansky-Pudlak Syndrome. <i>Journal of Immunology</i> , 2006, 176, 4361-4368.	0.4	47
151	Lymphangiomyomatosis. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 15.	0.2	7
152	Comparative Signature-Tagged Mutagenesis Identifies Pseudomonas Factors Conferring Resistance to the Pulmonary Collectin SP-A. <i>PLoS Pathogens</i> , 2005, 1, e31.	2.1	33
153	Pulmonary Surfactant Protein A Activates a Phosphatidylinositol 3-Kinase/Calcium Signal Transduction Pathway in Human Macrophages: Participation in the Up-Regulation of Mannose Receptor Activity. <i>Journal of Immunology</i> , 2005, 175, 2227-2236.	0.4	46
154	Surfactant Protein A Is a Principal and Oxidation-sensitive Microbial Permeabilizing Factor in the Alveolar Lining Fluid. <i>Journal of Biological Chemistry</i> , 2005, 280, 25913-25919.	1.6	24
155	Pulmonary Surfactant Protein A Inhibits Macrophage Reactive Oxygen Intermediate Production in Response to Stimuli by Reducing NADPH Oxidase Activity. <i>Journal of Immunology</i> , 2004, 172, 6866-6874.	0.4	72
156	Interactions of Pulmonary Collectins with <i>Bordetella bronchiseptica</i> and <i>Bordetella pertussis</i> Lipopolysaccharide Elucidate the Structural Basis of Their Antimicrobial Activities. <i>Infection and Immunity</i> , 2004, 72, 7124-7130.	1.0	31
157	<i>Bordetella pertussis</i> Lipopolysaccharide Resists the Bactericidal Effects of Pulmonary Surfactant Protein A. <i>Journal of Immunology</i> , 2004, 173, 1959-1965.	0.4	54
158	Surfactant lipid peroxidation damages surfactant protein A and inhibits interactions with phospholipid vesicles. <i>Journal of Lipid Research</i> , 2004, 45, 1061-1068.	2.0	28
159	Pulmonary Surfactant Protein-A (SP-A) Restores the Surface Properties of Surfactant after Oxidation by a Mechanism That Requires the Cys6 Interchain Disulfide Bond and the Phospholipid Binding Domain. <i>Journal of Biological Chemistry</i> , 2003, 278, 20461-20474.	1.6	35
160	Macrophage-independent Fungicidal Action of the Pulmonary Collectins. <i>Journal of Biological Chemistry</i> , 2003, 278, 36250-36256.	1.6	115
161	Crystal Structure of Trimeric Carbohydrate Recognition and Neck Domains of Surfactant Protein A. <i>Journal of Biological Chemistry</i> , 2003, 278, 43254-43260.	1.6	95
162	Recurrent Lymphangiomyomatosis after Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 167, 976-982.	2.5	231

#	ARTICLE	IF	CITATIONS
163	Surfactant Protein A Inhibits Lipopolysaccharide-Induced In Vivo Production of Interleukin-10 by Mononuclear Phagocytes during Lung Inflammation. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 28, 347-353.	1.4	25
164	Lymphangioliomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1405-1406.	2.5	6
165	Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. <i>Journal of Clinical Investigation</i> , 2003, 111, 1589-1602.	3.9	345
166	Pulmonary Surfactant Protein A Up-Regulates Activity of the Mannose Receptor, a Pattern Recognition Receptor Expressed on Human Macrophages. <i>Journal of Immunology</i> , 2002, 169, 3565-3573.	0.4	144
167	Cutting Edge: The Immunostimulatory Activity of the Lung Surfactant Protein-A Involves Toll-Like Receptor 4. <i>Journal of Immunology</i> , 2002, 168, 5989-5992.	0.4	305
168	Pulmonary Cysts Consistent With Lymphangioliomyomatosis Are Common in Women With Tuberous Sclerosis. <i>Chest</i> , 2002, 121, 61S.	0.4	16
169	The Role of Pulmonary Collectin N-terminal Domains in Surfactant Structure, Function, and Homeostasis in Vivo. <i>Journal of Biological Chemistry</i> , 2002, 277, 26971-26979.	1.6	42
170	Pulmonary surfactant and inflammation in septic adult mice: role of surfactant protein A. <i>Journal of Applied Physiology</i> , 2002, 92, 809-816.	1.2	12
171	The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. <i>Journal of Clinical Investigation</i> , 2002, 109, 707-712.	3.9	286
172	The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. <i>Journal of Clinical Investigation</i> , 2002, 109, 707-712.	3.9	164
173	Pulmonary cysts consistent with lymphangioliomyomatosis are common in women with tuberous sclerosis: genetic and radiographic analysis. <i>Chest</i> , 2002, 121, 61S.	0.4	7
174	Functional Mapping of Surfactant Protein A. <i>Fetal and Pediatric Pathology</i> , 2001, 20, 293-318.	0.3	8
175	Domains of surfactant protein A that affect protein oligomerization, lipid structure and surface tension. <i>Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology</i> , 2001, 129, 109-127.	0.8	52
176	The Collagen-like Region of Surfactant Protein A (SP-A) Is Required for Correction of Surfactant Structural and Functional Defects in the SP-A Null Mouse. <i>Journal of Biological Chemistry</i> , 2001, 276, 38542-38548.	1.6	42
177	Surfactant Protein A Suppresses Lipopolysaccharide-Induced IL-10 Production by Murine Macrophages. <i>Journal of Immunology</i> , 2001, 166, 6376-6382.	0.4	22
178	Immunosuppressed Surfactant Protein A-Deficient Mice Have Increased Susceptibility to Pneumocystis carinii Infection. <i>Journal of Infectious Diseases</i> , 2001, 183, 943-952.	1.9	71
179	Pulmonary-specific expression of SP-D corrects pulmonary lipid accumulation in SP-D gene-targeted mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 278, L365-L373.	1.3	69
180	Pulmonary Surfactant Proteins A and D Are Potent Endogenous Inhibitors of Lipid Peroxidation and Oxidative Cellular Injury. <i>Journal of Biological Chemistry</i> , 2000, 275, 38848-38855.	1.6	141

#	ARTICLE	IF	CITATIONS
181	Two Rat Surfactant Protein A Isoforms Arise by a Novel Mechanism That Includes Alternative Translation Initiation. <i>Biochemistry</i> , 2000, 39, 10189-10195.	1.2	5
182	Three-Dimensional Structure of Rat Surfactant Protein A Trimers in Association with Phospholipid Monolayers. <i>Biochemistry</i> , 2000, 39, 6310-6316.	1.2	26
183	Normal Surfactant Pool Sizes and Inhibition-Resistant Surfactant from Mice That Overexpress Surfactant Protein A. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 21, 380-387.	1.4	53
184	Deletion Mapping of N-terminal Domains of Surfactant Protein A. <i>Journal of Biological Chemistry</i> , 1999, 274, 3173-3181.	1.6	38
185	Interactions of pulmonary surfactant protein SP-A with monolayers of dipalmitoylphosphatidylcholine and cholesterol: roles of SP-A domains. <i>Journal of Lipid Research</i> , 1999, 40, 920-929.	2.0	24
186	Site-directed mutagenesis of surfactant protein A reveals dissociation of lipid aggregation and lipid uptake by alveolar type II cells. <i>BBA - Proteins and Proteomics</i> , 1998, 1387, 433-446.	2.1	14
187	Structure, processing and properties of surfactant protein A. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1408, 109-131.	1.8	108
188	Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis. <i>American Journal of Human Genetics</i> , 1998, 62, 810-815.	2.6	298
189	The Longer Isoform and Cys-1 Disulfide Bridge of Rat Surfactant Protein A Are Not Essential for Phospholipid and Type II Cell Interactions. <i>Biochemistry</i> , 1998, 37, 16481-16488.	1.2	11
190	Mutational Analysis of Arg197 of Rat Surfactant Protein A. <i>Journal of Biological Chemistry</i> , 1998, 273, 5702-5707.	1.6	19
191	Surfactant protein A inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L679-L686.	1.3	68
192	Identification of a Putative Precursor to the Major Surface Glycoprotein of <i>Pneumocystis carinii</i> . <i>Infection and Immunity</i> , 1998, 66, 741-746.	1.0	35
193	The Cys6 Intermolecular Disulfide Bond and the Collagen-like Region of Rat SP-A Play Critical Roles in Interactions with Alveolar Type II Cells and Surfactant Lipids. <i>Journal of Biological Chemistry</i> , 1997, 272, 27971-27979.	1.6	65
194	The Carbohydrate Recognition Domain of Surfactant Protein A Mediates Binding to the Major Surface Glycoprotein of <i>Pneumocystis carinii</i> . <i>Biochemistry</i> , 1997, 36, 8092-8099.	1.2	79
195	Alternate Amino Terminal Processing of Surfactant Protein A Results in Cysteiny Isoforms Required for Multimer Formation. <i>Biochemistry</i> , 1997, 36, 7018-7025.	1.2	42
196	Alanine Mutagenesis of Surfactant Protein A Reveals That Lipid Binding and pH-Dependent Liposome Aggregation Are Mediated by the Carbohydrate Recognition Domain. <i>Biochemistry</i> , 1997, 36, 13963-13971.	1.2	39
197	The 85-kDa, Arachidonic Acid-Specific Phospholipase A2 Is Expressed as an Activated Phosphoprotein in Sf9 Cells. <i>Archives of Biochemistry and Biophysics</i> , 1993, 306, 534-540.	1.4	43
198	Idiopathic Pulmonary Fibrosis: Abnormalities in the Bronchoalveolar Lavage Content of Surfactant Protein A. <i>The American Review of Respiratory Disease</i> , 1991, 144, 160-166.	2.9	108

#	ARTICLE	IF	CITATIONS
199	Expression and characterization of rat surfactant protein A synthesized in Chinese hamster ovary cells. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1990, 1087, 190-198.	2.4	12